Abcam, ab263322, Human PTS (PTPS) knockout HeLa cell lysate

Size: 1Kit
PTS KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 20 bp deletion in exon 1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 20 bp deletion in exon 1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PTS, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PTS/PTPS also known as 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase is an enzyme involved in the biosynthesis of tetrahydrobiopterin (BH4). Its molecular weight is approximately 23 kDa. The enzyme is expressed in various tissues including the liver kidney and brain. The enzyme catalyzes a step in the conversion of 78-dihydroneopterin triphosphate to 6-pyruvoyl tetrahydropterin which is an important step in the BH4 production pathway.
Biological function summary
PTS/PTPS plays a significant role in neurotransmitter synthesis and regulation. BH4 acts as a cofactor for several hydroxylase enzymes these enzymes include phenylalanine hydroxylase tyrosine hydroxylase and tryptophan hydroxylase. PTS/PTPS contributes to the production of neurotransmitters like dopamine serotonin and nitric oxide through its role in the biosynthesis of BH4. The protein functions as a part of a complex that includes other biosynthetic enzymes involved in the same pathway.
Pathways
PTS/PTPS is essential in the pathways involved in neurotransmitter metabolism and amino acid hydroxylation. The enzyme is intimately associated with the phenylalanine tyrosine and tryptophan metabolic pathways. In these pathways it interacts with proteins such as phenylalanine hydroxylase and nitric oxide synthase supporting the conversion of amino acids into critical neurotransmitters and molecules for physiological processes.
PTS/PTPS dysfunction links to neurological conditions and metabolic disorders. Mutations or deficiencies in the enzyme are associated with hyperphenylalaninemia due to BH4 deficiency impacting phenylalanine metabolism and leading to severe neurological symptoms. Another related disorder is dystonia a movement disorder where altered dopamine biosynthesis occurs. The interactions with enzymes like phenylalanine hydroxylase become disrupted further influencing the disease mechanisms and contributing to symptoms.